Published in Cancer Weekly, September 15th, 1997
The NIH Grant is a renewal of a National Cooperative Drug Discovery Grant (NCDDG) supporting the development of a "Trojan horse" approach to treating HIV infections called "Capsid Targeted Viral Inactivation" (CTVI). In this approach, Avigen and its collaborators deliver to HIV-infected cells a gene coding for a modified version of one of the HIV proteins.
When the virus replicates in a cell...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.